Modulating the Vaginal Microbiome After Implantation Failure

NCT ID: NCT03843112

Last Updated: 2021-03-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-01

Study Completion Date

2021-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaginal microbiome has in studies shown a link with the outcome of fertility treatment. The investigators wish to determine if it is possible to change an unfavorable vaginal microbiome using lactobacilli loaded vaginal supplements.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Implantation Failure Infertility, Female Vaginal Flora Imbalance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomised placebo controlled, double blinded study
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Participants, investigator, care providers and outcome assessors are all blinded until the end of inclusion af the last subject.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vivag Plus

Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.

Group Type ACTIVE_COMPARATOR

Vivag Plus

Intervention Type DRUG

Contains two lactobacilli strains; l. gasseri and l. rhamnosus

Placebo

Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.

Group Type PLACEBO_COMPARATOR

Placebo - Cap

Intervention Type DRUG

Vaginal supplements

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vivag Plus

Contains two lactobacilli strains; l. gasseri and l. rhamnosus

Intervention Type DRUG

Placebo - Cap

Vaginal supplements

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo vaginal capsule

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* unfavorable vaginal microbiome using ARTPreds test
* non-smoker

Exclusion Criteria

* use of oral antibiotics oral probiotics between diagnosis and inclusion in the study
* pregnancy at inclusion
* allergy towards study drugs
Minimum Eligible Age

18 Years

Maximum Eligible Age

43 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ARTPred

UNKNOWN

Sponsor Role collaborator

Bifodan A/S

UNKNOWN

Sponsor Role collaborator

Zealand University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nicholas Macklon

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fertilitetsklinikken, Region Sjælland

Køge, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Jepsen IE, Saxtorph MH, Englund ALM, Petersen KB, Wissing MLM, Hviid TVF, Macklon N. Probiotic treatment with specific lactobacilli does not improve an unfavorable vaginal microbiota prior to fertility treatment-A randomized, double-blinded, placebo-controlled trial. Front Endocrinol (Lausanne). 2022 Dec 1;13:1057022. doi: 10.3389/fendo.2022.1057022. eCollection 2022.

Reference Type DERIVED
PMID: 36531460 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REG-076-2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TOL-463 Phase 2 Study for Vaginitis
NCT02866227 COMPLETED PHASE2